Review: Oral glycoprotein IIb/IIIa inhibitors increase mortality and myocardial infarction
- Role of glycoprotein IIb/IIIa-receptor inhibitors in managing ST-segment-elevation myocardial infarction. Racine, Eric // American Journal of Health-System Pharmacy;11/1/2002 Supplement 7, Vol. 59, p27
The role of glycoprotein (GP) IIb/ IIIa-receptor inhibitors in managing ST-segment-elevation (STE) myocardial infarction (MI) is discussed. Strategies to improve outcomes in patients with STE MI have been directed toward rapidly establishing early reperfusion of the infarct-related artery and...
- Cost and effectiveness of glycoprotein IIb/IIIa-receptor inhibitors in patients with acute myocardial infarction undergoing percutaneous coronary intervention. McCollam, Patrick L.; Foster, David A.; Riesmeyer, Jeffrey S. // American Journal of Health-System Pharmacy;6/15/2003, Vol. 60 Issue 12, p1251
Studies outcomes in patients with acute myocardial infarction who received adjunctive therapy with glycoprotein IIb/IIIa-receptor inhibitors during percutaneous coronary intervention. Potential of abciximab; Cost-effectiveness ratio.
- Reimbursement mechanisms for glycoprotein IIb/IIIa-receptor inhibitors. DiDomenico, Robert J. // American Journal of Health-System Pharmacy;11/1/2002 Supplement 7, Vol. 59, p37
Changes in health care reimbursement policies as they apply to glyco-protein (GP) IIb/IIIa-receptor inhibitors are discussed. GP IIb/IIIa-receptor inhibitors significantly reduce the frequency of myocardial infarction and death in patients with non-ST-segment-elevation (NSTE) acute coronary...
- Increased Alpha-1-Acid Glycoprotein and Lidocaine Disposition in Myocardial Infarction. Routledge, Philip A.; Stargel, Wayne W.; Wagner, Galen S.; Shand, David G. // Annals of Internal Medicine;Nov80, Vol. 93 Issue 5, p701
Reports on the measurement of alpha-1-acid glycoprotein concentration in patients with myocardial infarction. Method used to measure the glycoprotein; Information on the prolonged infusions of lidocaine; Effect of increased lidocaine binding.
- 153 Left ventricle mural thrombus early after acute myocardial infarction in the era of primary percutaneous intervention and glycoprotein IIb/IIIa inhibitors Zielinska, M.; Kaczmarek, K.; Goch, J.H. // European Journal of Echocardiography;Dec2006 Supplement 1, Vol. 7, pS2
An abstract of the article "Left ventricle mural thrombus early after acute myocardial infarction in the era of primary percutaneous intervention and glycoprotein IIb/IIIa inhibitors," by M. Zielinska, K. Kaczmarek, and J. H. Goch is presented.
- Anti-Thrombotic, Anti-Platelet and Fibrinolytic Therapy: Current Management of Acute Myocardial Infarction. Worthley,, Stephen G.; Helft, G�rard; Worthley, Stephen G. // Heart, Lung & Circulation;Oct2001, Vol. 10 Issue 2, p68
Significant advances in the treatment of patients with acute myocardial infarction (MI) have been obtained in recent times. In particular, thrombolytic therapy has been shown to preserve ventricular function and improve survival in patients with acute MI. Therapies now include third-generation...
- Facilitated Thrombolysis: Dethrombosis? Luciardi, H�ctor; Berman, Sof�a; Muntaner, Juan; De la Serna, Fernando; Altman, Ra�l // Clinical & Applied Thrombosis/Hemostasis;Apr2002, Vol. 8 Issue 2, p133
Intracoronary thrombus formation results from the combined effects of platelet aggregation and fibrin formation. Fibrinogen plays a significant role in each of these components. Dethrombosis is a therapeutic approach that allows dissolution of a recent thrombus while avoiding the potent...
- Activin A Levels Are Associated With Abnormal Glucose Regulation in Patients With Myocardial Infarction. Andersen, Geir Ø.; Ueland, Thor; Knudsen, Eva C.; Scholz, Hanne; Yndestad, Arne; Sahraoui, Afaf; Smith, Camilla; Lekva, Tove; Otterdal, Kari; Halvorsen, Bente; Seljeflot, Ingebjørg; Aukrust, Pål // Diabetes;May2011, Vol. 60 Issue 5, p1544
OBJECTIVE--On the basis of the role of activin A in inflammation, atherogenesis, and glucose homeostasis, we investigated whether activin A could be related to glucometabolic abnormalities in patients with acute myocardial infarction (MI). RESEARCH DESIGN AND METHODS--Activin A measurement and...
- Stenting plus a Platelet Glycoprotein Inhibitor Salvaged More Myocardium after Myocardial Infarction Than Did Accelerated Alteplase Infusion. A., Schomig; A., Kastrati; J., Dirschinger; Frishman, William H. // Annals of Internal Medicine;9/18/2001, Vol. 135 Issue 6, p441
Examines the efficacy of various intervention techniques for myocardial infarction in the United States. Improvement of epicardial blood flow and microcirculation; Combination of alteplase and platelet glycoprotein inhibitor to stabilize patients; Significance of less myocardial damage in...